Vericel reports third quarter revenue of $67.5 million
Vericel Corporation reported third quarter 2025 total net revenue of $67.5 million, up from $57.9 million in the same period in 2024. MACI net revenue grew 25% to $55.7 million, while Epicel net revenue was $10.4 million and NexoBrid net revenue was $1.5 million. Gross margin reached 73.5%, compared to 71.9% in the prior year. Net income for the quarter was $5.1 million, or $0.10 per diluted share, compared to a net loss of $0.9 million, or $0.02 per diluted share, in the third quarter of 2024. Non-GAAP adjusted EBITDA was $17.0 million, or 25% of net revenue, up from $10.0 million, or 17%, in the prior year. The company reported operating cash flow of $22.1 million and ended the quarter with $185 million in cash and investments, with no debt. More than 800 surgeons have been trained in MACI arthro procedures to date. Full-year revenue guidance is $272 to $276 million, with MACI revenue expected in the low 20% growth range.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vericel Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569795-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.